Biotech upstart goes the crowdfunding route to develop its obesity drug

Philadelphia startup Symmetry Therapeutics has an early-stage weight-loss treatment and ambitions of clinical development. Now, thanks to a crowdfunding campaign, the biotech has enough cash to move forward. As the Philadelphia Business Journal reports, Symmetry met its goal of raising just over $30,000 on Indiegogo, money that will support preclinical research on SYM401, a small-molecule therapy designed to burn fat. Story

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.